B-Secur Collaborates with Texas Instruments

B-Secur today announced it has launched an electrocardiogram (ECG/EKG) solution based on the Texas Instruments (TI) AFE4950 analog front end (AFE) for photoplethysmography (PPG) and ECG/EKG sensing that will accelerate the design of next-generation consumer wearables.

The integration provides high-performing sensing capabilities for wearable devices like premium smartwatches and Wi-Fi-connected optical heart-rate monitors, and enables advanced features for identification, wellness and health monitoring in Internet of Things (IoT) devices.

It is the industry’s first solution with a fully integrated ECG/EKG and PPG signal chain that allows for synchronous sampling of cardiac activity with dry electrodes used in battery-operated products.

It follows an announcement from B-Secur that it has received U.S. Food and Drug Administration (FDA) clearance for its innovative HeartKey® ECG/EKG software.

The combination of HeartKey® and TI’s AFE4950 enables device manufacturers and partners around the world to eliminate months of R&D with a fully integrated sensor, electrical and signal processing solution. It is a key development enabling heart-health features to become widely available in the fast-paced and rapidly evolving consumer wearables sector.

The collaboration is part of B-Secur’s drive to speed up the development and adoption of high-performance biosensing solutions by device manufacturers worldwide.

Ben Carter, Chief Commercial Officer, B-Secur commented: “It is a key strategic development for B-Secur to announce this integration with Texas Instruments and our FDA-cleared HeartKey® software today. As more and more wearable and IoT devices adopt ECG/EKG technology, supplying a fully integrated, high-performance solution with Texas Instruments means our customers around the world can bring their own consumer wearable products to market quicker and with greater confidence.”

Karthik Soundarapandian, product line manager for medical imaging at TI, said: “The trend in consumer electronics is to add more health monitoring into smartwatches and other wearables. This, in combination with a patient’s medical history, can help health professionals with early detection and prevention of disease. The precision signal quality from the AFE4950-based hardware, combined with B-Secur’s algorithms, will help wearables manufacturers design solutions that make clinical-quality monitoring more accessible to a wider population.”

B-Secur’s HeartKey® consists of a suite of powerful ECG/EKG algorithms that uniquely combine user identification, health, and wellness to generate accurate data encrypted through the user’s unique heartbeat.

Cardiovascular disease (CVD) is the number one cause of death globally with an estimated 17.9 million people dying from the disease each year representing 31% of all global deaths.

SourceB-Secur

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”